HK1051066A1 - 作為異常細胞生長標記的pin1 - Google Patents

作為異常細胞生長標記的pin1

Info

Publication number
HK1051066A1
HK1051066A1 HK03101543.7A HK03101543A HK1051066A1 HK 1051066 A1 HK1051066 A1 HK 1051066A1 HK 03101543 A HK03101543 A HK 03101543A HK 1051066 A1 HK1051066 A1 HK 1051066A1
Authority
HK
Hong Kong
Prior art keywords
pin1
cell growth
abnormal cell
marker
levels
Prior art date
Application number
HK03101543.7A
Other languages
English (en)
Inventor
Ping Lu Kun
Wulf Gerburg
Zhen Zhou Xiao
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of HK1051066A1 publication Critical patent/HK1051066A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
HK03101543.7A 1999-11-29 2003-02-28 作為異常細胞生長標記的pin1 HK1051066A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16780099P 1999-11-29 1999-11-29
US25367600P 2000-11-28 2000-11-28
PCT/US2000/032560 WO2001038878A2 (en) 1999-11-29 2000-11-29 Pin1 as a marker for abnormal cell growth

Publications (1)

Publication Number Publication Date
HK1051066A1 true HK1051066A1 (zh) 2003-07-18

Family

ID=26863487

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101543.7A HK1051066A1 (zh) 1999-11-29 2003-02-28 作為異常細胞生長標記的pin1

Country Status (7)

Country Link
EP (1) EP1234185B1 (zh)
JP (1) JP2003515172A (zh)
AT (1) ATE400814T1 (zh)
CA (1) CA2392917C (zh)
DE (1) DE60039453D1 (zh)
HK (1) HK1051066A1 (zh)
WO (1) WO2001038878A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532390A (ja) 2001-02-09 2004-10-21 ピンテックス ファーマシューティカルズ，インク． 前立腺癌のマーカとしてのｐｉｎ１
CA2437807A1 (en) * 2001-02-09 2002-08-22 Pintex Pharmaceuticals, Inc. Pin1 as marker for abnormal cell growth
EP1436624B1 (en) * 2001-09-12 2012-03-21 The Walter And Eliza Hall Institute Of Medical Research A method of diagnosis and treatment and agents useful for same
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
EP1572236A4 (en) * 2002-11-14 2007-01-03 Pintex Pharmaceuticals Inc PINE RATE1 IN HEALTHY FABRIC AND IN CANCER FABRIC
WO2022032179A1 (en) * 2020-08-07 2022-02-10 The Regents Of The University Of California Pin1 inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972697A (en) * 1995-11-13 1999-10-26 The Salk Institute For Biological Studies NIMA interacting proteins
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions

Also Published As

Publication number Publication date
ATE400814T1 (de) 2008-07-15
CA2392917C (en) 2007-05-01
EP1234185A2 (en) 2002-08-28
WO2001038878A2 (en) 2001-05-31
WO2001038878A3 (en) 2002-01-17
CA2392917A1 (en) 2001-05-31
JP2003515172A (ja) 2003-04-22
DE60039453D1 (de) 2008-08-21
EP1234185B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
WO2002065091A3 (en) Pin1 as marker for abnormal cell growth
MXPA03003281A (es) Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
WO2004000102A3 (en) Method for predicting response to epidermal growth factor receptor-directed therapy
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
DE60025713D1 (de) Nukleinsäuresequenzen für proteine, die an der tocopherolbiosynthese beteiligt sind
PT1319062E (pt) Processo e dispositivo para cultivo e/ou tratamento de células
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
ATE463092T1 (de) Busmodem für gebäude- und industrielle elektrische systeme
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
AU2163300A (en) Plant 1-deoxy-d-xylulose 5-phosphate reductoisomerase
AU2003302732A1 (en) Method for identifying risk of breast cancer and treatments thereof
ATE354544T1 (de) Verhinderung des zellwachstums in einem gewässer
GB0208041D0 (en) Method of culturing animal cells
ATE365217T1 (de) Nukelinsäuresequenzen für proteine, die an der tocopherolbiosynthese beteiligt sind
HK1051066A1 (zh) 作為異常細胞生長標記的pin1
ATE519772T1 (de) Vorrichtung und system mit trockener kontrollgen- verstummungszusammensetzung
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
DE60036551D1 (de) VERWENDUNG VON BAKTERIELLEN ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM ZUR TÖTUNG VON EUKARYOTISCHEN ZELLEN
TW200510011A (en) A method for regeneration of bone
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
WO2004003152A3 (en) Sos1 inhibitors
EP1601682A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER